New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Moderna, Inc.

MRNA

Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
n/m
Free cash flow
n/m
Total debt
+13,550.0%

Quarter to September 2026, against a year earlier

195.12 4.21 −2.11%

After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.

Market cap
$79.6B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
3/9
ROIC
−35.1%
Net debt / EBITDA
1.8×
Payout ratio
—

Revenue to profit Twelve months to Sep 30, 2026

It lost $2.8B on $2.5B of revenue: $110.46 for every $100. Gross margin has risen two quarters running, from 22.1% to 28.0%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue2.5100.0%
Cost of revenue−1.8−72.0%
Gross profit0.728.0%
Research & development−2.7−105.3%
Selling, general & admin−1.0−38.8%
Operating income−2.9−116.0%
Other income, net+0.28.0%
Income tax−0.1−2.4%
Net income−2.8−110.5%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$1.9B$2.2B$2.2B$2.5B
Operating income−$3.1B−$3.4B−$3.3B−$2.9B
Net income−$2.8B−$3.2B−$3.2B−$2.8B
Net margin (right axis)−145.2%−143.6%−141.4%−110.5%
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Revenue

+8 more TTM periods

1,944.00 2,225.00 2,228.00 2,525.00
Cost of Revenue
868.00 1,733.00 1,707.00 1,818.00
Gross Profit
1,076.00 492.00 521.00 707.00
R&D Expenses
3,132.00 2,925.00 2,876.00 2,658.00
SG&A Expenses
1,018.00 979.00 965.00 979.00
Operating Income
(3,074.00) (3,412.00) (3,320.00) (2,930.00)
Non-operating Income/Expense
306.00 274.00 233.00 201.00
EBT
(2,768.00) (3,138.00) (3,087.00) (2,729.00)
Income Tax Provision
54.00 56.00 64.00 60.00
Income after Tax
(2,822.00) (3,194.00) (3,151.00) (2,789.00)
Net Income Common
(2,822.00) (3,194.00) (3,151.00) (2,789.00)
EPS (Basic)
(7.27) (8.15) (7.99) (7.08)
EPS (Diluted)
(7.27) (8.15) (7.99) (7.10)
Shares (Basic, Weighted)
388.25 390.50 393.00 395.75
Shares (Diluted, Weighted)
388.25 390.50 393.00 403.00
Gross Margin
55.35% 22.11% 23.38% 28.00%
EBIT Margin
(158.13%) (153.35%) (149.01%) (116.04%)
EBT margin
(142.39%) (141.03%) (138.55%) (108.08%)
Net Profit Margin
(145.16%) (143.55%) (141.43%) (110.46%)
Free Cash Flow Margin
(106.74%) (72.04%) (55.83%) (80.95%)
EBITDA
(2,926.00) (3,236.00) (3,130.00) (2,719.00)
EBIT
(3,074.00) (3,412.00) (3,320.00) (2,930.00)
EPS (Diluted, from Cont. Ops)
(7.25) (8.14) (7.98) (7.09)
EPS (Diluted, Consolidated)
(7.25) (8.14) (7.98) (7.09)
EPS (Basic, Consolidated)
(7.25) (8.14) (7.98) (7.06)
Shares (Diluted, Average)
389.00 391.25 393.75 403.75
EPS (Basic, from Continuous Ops)
(7.25) (8.14) (7.98) (7.06)
Income from Continuous Operations
(2,822.00) (3,194.00) (3,151.00) (2,789.00)
Consolidated Net Income/Loss
(2,822.00) (3,194.00) (3,151.00) (2,789.00)
EBITDA Margin
(150.51%) (145.44%) (140.48%) (107.68%)
Operating Cash Flow Margin
(96.35%) (65.89%) (48.16%) (70.69%)

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 11, 2026